Genitourinary Oncology News

Nephron-Sparing and Chemoablation in Upper Tract Urothelial Carcinoma

At the Society of Urologic Oncology Annual Meeting, Katie S. Murray, DO, NYU Grossman School of Medicine, and Christopher Wallis, MD, PhD, FRCSC, University of Toronto, discuss the nuances of chemoablation and renal preservation in upper tract urothelial carcinoma.

They highlight including optimal patient selection, size criteria, and how surgical ablation and chemoablation can fit together.

Latest News

Five-Item Frailty Index Can Increase Prognosis, Decision-Making in Patients With UTUC After RNU

Emily MenendezUpper Tract Urothelial Carcinoma | December 8, 2023

Use of an sFI may increase accuracy in predicting complications and prognosis, as well as improve decision-making.

When to Consider Intravesical Therapy Versus Chemoablation in NMIBC

Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023

The panel conclude with their thoughts on considerations for TURBT and intravesical therapy versus chemoablation.

Emerging Therapies in Pretreated NMIBC

Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023

The panel considers therapies across different risk stratifications, including ATLAS, ENVISION, and BOND-003 studies.

Current Evaluation and Treatment Pathways for Low-Grade, Intermediate-Risk NMIBC

Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023

The panel delves into treatment pathways, including considerations for ablation and repeated histologic evaluation.

Risk Stratification in NMIBC and Classification of Low-Grade, Intermediate-Risk Disease

Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023

The panel kicked off with conversations about risk stratification and classification of low-grade, intermediate-risk disease.

ASCO Updates Recommendations for Lutetium-177-PSMA-617 in mCRPC

Zachary BessetteCRPC | December 6, 2023

ASCO has provided a rapid update on its guideline recommendations for 177Lutetium-PSMA-617 in mCRPC.

Safety, Efficacy of Disitamab Vedotin in Patients With HER2-Positive Locally Advanced or Metastatic UC

Zachary BessetteAdvanced Urothelial Carcinoma | December 5, 2023

A recent combined analysis of 2 phase 2 studies indicates that disitamab vedotin has a promising efficacy and safety profile.

FDA Grants Priority Review to EV Plus Pembrolizumab, Nivolumab Plus Chemotherapy for First-line la/mUC

Zachary BessetteAdvanced Urothelial Carcinoma | December 5, 2023

The FDA is granting a priority review for EV/pembro as well as nivo/chemo for the treatment of patients with la/mUC.

PSMAfore: Control Arm and Sequencing Considerations

Oliver Sartor, MDRLT | December 4, 2023

Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.

PSMAfore: Methodology, Nuances, and Implications

Oliver Sartor, MDRLT | December 4, 2023

Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.

Is There an Expanded Role for Enzalutamide in Prostate Cancer?

David Ambinder, MDLocalized | December 4, 2023

Enzalutamide plus leuprolide and enzalutamide monotherapy resulted in significantly MFS and a longer time to PSA progression.

Academic Solutions to Cost Containment, Financial Toxicity

Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 1, 2023

Drs. Joyce and Wallis consider the impact of financial toxicity and containing costs for patients with GU malignancies.

Editorial Advisory Board

Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center

Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital

Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine

Jérémie Calais, MD, MScEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles

Akhil Abraham Saji, MDAssociate Editor | Fellow at the University of Southern California

David Ambinder, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center

Expert Interviews

Mark T. Fleming, MD – Ushering Early-Phase Prostate Cancer Therapies from Development to Everyday Treatment

Mark T. Fleming, MDProstate Cancer | October 18, 2023

Dr. Fleming details his early-phase clinical trial work that has had the largest impact on patients with GU malignancies.

SWOG S1605 Yields “Modest” Efficacy for Atezolizumab in BCG-Unresponsive High-Risk NMIBC

Peter C. Black, MDNon-Muscle Invasive Urothelial Carcinoma | September 29, 2023

Dr. Black shares the basis for testing atezolizumab in BCG-unresponsive NMIBC as well as the implications of SWOG S1605.

Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care

Hans Hammers, MD, PhDRenal Cell Carcinoma | September 8, 2023

Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.

Precision Therapy for MIBC: Novel Treatments Helping, Biomarkers Lacking

Guru P. Sonpavde, MDMuscle Invasive Urothelial Carcinoma | August 31, 2023

Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC.

Emerging Targeted Therapies in Bladder Cancer: Frontline Options and Beyond

Arlene O. Siefker-Radtke, MDAdvanced Urothelial Carcinoma | July 12, 2023

Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.

Pavlos Msaouel, MD, PhD – Leading the Way in Renal Medullary Carcinoma

Pavlos Msaouel, MD, PhDRenal Cell Carcinoma | August 23, 2023

Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer

CRPC

Localized

Phenotypic Precision Medicine in Advanced Prostate Cancer

RLT

Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Testicular, Penile, and Rare Malignancies

Urothelial Carcinoma

Advanced Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Prostate Cancer

CRPC

Localized

Phenotypic Precision Medicine in Advanced Prostate Cancer

GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.

Get research and breaking news straight to your inbox.

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Episode 281: Paper of The Month - Lu-177 With Pembrolizumab in Prostate Cancer

Dr. Rahul Aggarwal discusses his recent paper on a phase 1/2 study on Lu-177 with pembrolizumab for mCRPC.

# Posted on December 8, 2023

# Uromigos-Prostate Cancer

Episode 280: IKCS 2023 Overview

Tian Zhang joins the podcast to give an overview of some of the panels presented at this year's IKCS meeting.

# Posted on November 17, 2023

# Uromigos-IKCS 2023

# Uromigos-Kidney Cancer

Episode 279: Management of IO-resistant RCC at #UromigosLive 2023

Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more.

# Posted on November 6, 2023

# Uromigos Live 2023-Renal Cell Carcinoma

Conference Coverage

Live meeting highlights

PSMAfore: Control Arm and Sequencing Considerations

Oliver Sartor, MDRLT | December 4, 2023

Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.

PSMAfore: Methodology, Nuances, and Implications

Oliver Sartor, MDRLT | December 4, 2023

Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.

Academic Solutions to Cost Containment, Financial Toxicity

Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 1, 2023

Drs. Joyce and Wallis consider the impact of financial toxicity and containing costs for patients with GU malignancies.

Impact of the Microbiome on Immune Therapy in Kidney Cancer

Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 1, 2023

Drs. Pal and Wallis break down the role of the microbiome and response in patients with kidney cancer.

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and information relevant to their patients and practices. Featuring the most current information from around the specialty, it offers insights and exclusive interviews from experts in the field.

Cancer Nursing Today delivers critical news and information to support oncology nurses throughout their education and careers, with the goal of advancing oncology treatments and care and promoting the nurse’s role in enhanced patient outcomes and quality of life.

Urban Health Today is the leading independent news source that provides urban healthcare professionals with relevant clinical news and policy developments that impact patients. Its coverage focuses on clinical, social, and environmental health disparities.

MashupMD is a leading medical news aggregator, optimized for rapid access to the latest headlines in the medical world, providing a collection, or “mashup,” of key medical content based on what your colleagues are reading and sharing on social media.